



## Prior Authorization Approval Criteria

### *Nexiclon XR (clonidine extended release)*

<b>Generic name:</b>	clonidine extended release
<b>Brand name:</b>	Nexiclon XR
<b>Medication class:</b>	Antiadrenergic Agents – Centrally Acting
<b>FDA-approved uses:</b>	Treatment of hypertension
<b>Available dosage forms:</b>	Suspension      0.09 mg/mL Tablets            0.17 mg 0.26 mg
<b>Usual dose:</b>	Therapy should be initiated with 0.17 mg daily, and the dosage should be adjusted in increments of 0.09 mg/day at weekly intervals until the desired response is achieved. Most common dose is between 0.17 and 0.52 mg daily. When discontinuing therapy, the dosage should be tapered over a period of 2 – 4 days.
<b>Approximate monthly cost:</b> (based on AWP 2011)	\$150-\$450/month for 0.17mg-0.52mg/day
<b>Duration of therapy:</b>	Indefinite

**Criteria for use** (*bullet points below are all inclusive unless otherwise noted*):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Must be clinically diagnosed with hypertension
- Failed / intolerant to thiazide diuretics.
- Failed / intolerant to ace inhibitors
- Failed/ intolerant to ARBs.
- Failed/ intolerant to beta blockers
- Failed / intolerant to calcium channel blockers
- Must have tried and failed two drug combinations
- Failed / intolerant to clonidine patch
- Failed / intolerant to oral immediate-release clonidine

**Monitoring:**

- Heart rate and blood pressure should be determined prior to initiation of therapy, following dosage increases, and periodically during therapy

**Contraindication:**

- Patients with known hypersensitivity to clonidine

**Not approved if:**

- Patient does not meet the above stated criteria
- Patient has any contraindications to the use of clonidine.

**Special considerations:**

- Tablets are scored and can be split

FCHP Pharmacy and Therapeutics Committee approval: \_\_\_\_\_

Date: \_\_\_\_\_

Adopted: 09/07/11